|
1
|
Tariq K and Rana F: TNBC vs. Non-TNBC: A
five-year retrospective review of differences in mean age, family
history, smoking history and stage at diagnosis at an Inner City
University Program. World J Oncol. 4:241–247. 2013.PubMed/NCBI View
Article : Google Scholar
|
|
2
|
Bianchini G, Balko JM, Mayer IA, Sanders
ME and Gianni L: Triple-negative breast cancer: Challenges and
opportunities of a heterogeneous disease. Nat Rev Clin Oncol.
13:674–690. 2016.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Jhan JR and Andrechek ER: Triple-negative
breast cancer and the potential for targeted therapy.
Pharmacogenomics. 18:1595–1609. 2017.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Nakhjavani M, Hardingham JE, Palethorpe
HM, Price TJ and Townsend AR: Druggable Molecular Targets for the
Treatment of Triple Negative Breast Cancer. J Breast Cancer.
22:341–361. 2019.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297.
2004.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Mohr AM and Mott JL: Overview of microRNA
biology. Semin Liver Dis. 35:3–11. 2015.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Fabian MR, Sonenberg N and Filipowicz W:
Regulation of mRNA translation and stability by microRNAs. Annu Rev
Biochem. 79:351–379. 2010.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Qu H, Xu W, Huang Y and Yang S:
Circulating miRNAs: Promising biomarkers of human cancer. Asian Pac
J Cancer Prev. 12:1117–1125. 2011.PubMed/NCBI
|
|
9
|
Momtazi AA, Shahabipour F, Khatibi S,
Johnston TP, Pirro M and Sahebkar A: Curcumin as a microRNA
regulator in cancer: A review. Rev Physiol Biochem Pharmacol.
171:1–38. 2016.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Iorio MV and Croce CM: MicroRNA
dysregulation in cancer: Diagnostics, monitoring and therapeutics.
A comprehensive review. EMBO Mol Med. 9(852)2017.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Kwak PB, Iwasaki S and Tomari Y: The
microRNA pathway and cancer. Cancer Sci. 101:2309–2315.
2010.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Rupaimoole R and Slack FJ: MicroRNA
therapeutics: Towards a new era for the management of cancer and
other diseases. Nat Rev Drug Discov. 16:203–222. 2017.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Piasecka D, Braun M, Kordek R, Sadej R and
Romanska H: MicroRNAs in regulation of triple-negative breast
cancer progression. J Cancer Res Clin Oncol. 144:1401–1411.
2018.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Petrovic N, Davidovic R, Bajic V,
Obradovic M and Isenovic RE: MicroRNA in breast cancer: The
association with BRCA1/2. Cancer Biomark. 19:119–128.
2017.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Wang C, Xu C, Niu R, Hu G, Gu Z and Zhuang
Z: miR-890 inhibits proliferation and invasion and induces
apoptosis in triple-negative breast cancer cells by targeting
CD147. BMC Cancer. 19(577)2019.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Zhang Y, Zhao Z, Li S, Dong L, Li Y, Mao
Y, Liang Y, Tao Y and Ma J: Inhibition of miR 214 attenuates the
migration and invasion of triple negative breast cancer cells. Mol
Med Rep. 19:4035–4042. 2019.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Ma Y, Yan F, Wei W, Deng J, Li L, Liu L
and Sun J: MicroRNA-598 inhibits the growth and maintenance of
gastric cancer stem-like cells by down-regulating RRS1. Cell Cycle.
18:2757–2769. 2019.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Tong X, Su P, Yang H, Chi F, Shen L, Feng
X, Jiang H, Zhang X and Wang Z: MicroRNA-598 inhibits the
proliferation and invasion of non-small cell lung cancer cells by
directly targeting ZEB2. Exp Ther Med. 16:5417–5423.
2018.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Chen J, Zhang H, Chen Y, Qiao G, Jiang W,
Ni P, Liu X and Ma L: miR-598 inhibits metastasis in colorectal
cancer by suppressing JAG1/Notch2 pathway stimulating EMT. Exp Cell
Res. 352:104–112. 2017.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Shimizu K, Chiba S, Saito T, Kumano K and
Hirai H: Physical interaction of Delta1, Jagged1, and Jagged2 with
Notch1 and Notch3 receptors. Biochem Biophys Res Commun.
276:385–389. 2000.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Grochowski CM, Loomes KM and Spinner NB:
Jagged1 (JAG1): Structure, expression, and disease associations.
Gene. 576:381–384. 2016.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Choi K, Ahn YH, Gibbons DL, Tran HT,
Creighton CJ, Girard L, Minna JD, Qin FX and Kurie JM: Distinct
biological roles for the notch ligands Jagged-1 and Jagged-2. J
Biol Chem. 284:17766–17774. 2009.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Zavadil J, Cermak L, Soto-Nieves N and
Böttinger EP: Integration of TGF-beta/Smad and Jagged1/Notch
signalling in epithelial-to-mesenchymal transition. EMBO J.
23:1155–1165. 2004.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Chen X, Stoeck A, Lee SJ, Shih IeM, Wang
MM and Wang TL: Jagged1 expression regulated by Notch3 and
Wnt/β-catenin signaling pathways in ovarian cancer. Oncotarget.
1:210–218. 2010.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Steg AD, Katre AA, Goodman B, Han HD, Nick
AM, Stone RL, Coleman RL, Alvarez RD, Lopez-Berestein G, Sood AK,
et al: Targeting the notch ligand JAGGED1 in both tumor cells and
stroma in ovarian cancer. Clin Cancer Res. 17:5674–5685.
2011.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Nagini S: Breast Cancer: Current Molecular
Therapeutic Targets and New Players. Anticancer Agents Med Chem.
17:152–163. 2017.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Wein L and Loi S: Mechanisms of resistance
of chemotherapy in early-stage triple negative breast cancer
(TNBC). Breast. 34 (Suppl 1):S27–S30. 2017.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Lehmann BD, Jovanović B, Chen X, Estrada
MV, Johnson KN, Shyr Y, Moses HL, Sanders ME and Pietenpol JA:
Refinement of Triple-Negative Breast Cancer Molecular Subtypes:
Implications for Neoadjuvant Chemotherapy Selection. PLoS One.
11(e0157368)2016.PubMed/NCBI View Article : Google Scholar
|
|
30
|
O'Reilly EA, Gubbins L, Sharma S, Tully R,
Guang MH, Weiner-Gorzel K, McCaffrey J, Harrison M, Furlong F, Kell
M, et al: The fate of chemoresistance in triple negative breast
cancer (TNBC). BBA Clin. 3:257–275. 2015.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Das S: Identification and targeting of
microRNAs modulating acquired chemotherapy resistance in Triple
negative breast cancer (TNBC): A better strategy to combat
chemoresistance. Med Hypotheses. 96:5–8. 2016.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Tang Q, Ouyang H, He D, Yu C and Tang G:
MicroRNA-based potential diagnostic, prognostic and therapeutic
applications in triple-negative breast cancer. Artif Cells Nanomed
Biotechnol. 47:2800–2809. 2019.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Gupta I, Sareyeldin RM, Al-Hashimi I,
Al-Thawadi HA, Al Farsi H, Vranic S and Al Moustafa AE: Triple
Negative Breast Cancer Profile, from Gene to microRNA, in Relation
to Ethnicity. Cancers (Basel). 11(363)2019.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Xing F, Wang S and Zhou J: The Expression
of MicroRNA-598 Inhibits Ovarian Cancer Cell Proliferation and
Metastasis by Targeting URI. Mol Ther Oncolytics. 12:9–15.
2018.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Wang N, Zhang Y and Liang H: MicroRNA-598
Inhibits Cell Proliferation and Invasion of Glioblastoma by
Directly Targeting Metastasis Associated in Colon Cancer-1 (MACC1).
Oncol Res. 26:1275–1283. 2018.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Li D, Masiero M, Banham AH and Harris AL:
The notch ligand JAGGED1 as a target for anti-tumor therapy. Front
Oncol. 4(254)2014.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Liu Z, Zhang G, Yu W, Gao N and Peng J:
miR-186 inhibits cell proliferation in multiple myeloma by
repressing Jagged1. Biochem Biophys Res Commun. 469:692–697.
2016.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Tang L, Yang B, Cao X, Li Q, Jiang L and
Wang D: MicroRNA-377-3p inhibits growth and invasion through
sponging JAG1 in ovarian cancer. Genes Genomics. 41:919–926.
2019.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Duan K, Ge YC, Zhang XP, Wu SY, Feng JS,
Chen SL, Zhang LI, Yuan ZH and Fu CH: miR-34a inhibits cell
proliferation in prostate cancer by downregulation of SIRT1
expression. Oncol Lett. 10:3223–3227. 2015.PubMed/NCBI View Article : Google Scholar
|
